Evaluation of the innovativeness of the domestic pharmaceutical sector projects within the framework of the R&D support programs
Wide public access to the effective and safe medicines has always been a priority for the Member States of the European Union, which was particularly noted during the Covid-19 pandemic. The European Commission has developed and adopted a Pharmaceutical Strategy which provides for actions to strength...
Main Authors: | Małgorzata Sznitowska, Monika Lamparska-Przybysz |
---|---|
Format: | Article |
Language: | Polish |
Published: |
Polish Pharmaceutical Society
2022-07-01
|
Series: | Farmacja Polska |
Subjects: | |
Online Access: | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2022%2F5%2F03_OG_Ocena_innowacyjnosci_n.pdf |
Similar Items
-
LIFE CYCLE OF THE PHARMACEUTICAL PRODUCT AND PRIMARY STRATEGIC GOALS
by: Cristina CIOT
Published: (2015-12-01) -
From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01) -
Generic drugs in ophthalmic practice: Boon or bane?
by: Murali Ariga, et al.
Published: (2017-01-01) -
The Innovativeness of Bio-Pharmaceutical Cluster or Import Substitution: the Development Priorities of the Economy Sector
by: Alexander Nickolaevich Tsatsulin, et al.
Published: (2018-04-01) -
The Innovativeness of Bio- Pharmaceutical Cluster or Import Substitution: the Development Priorities of the Economy Sector
by: Alexander Nickolaevich Tsatsulin, et al.
Published: (2018-04-01)